Everydayhealth.com, March 17, 2025: President Trump’s executive order will create a MAHA Commission to examine the use of ADHD and psychiatric drugs for children. This news article focuses on whether access to ADHD drugs will harm children. NCHR reassures parents that access is unlikely to be harmed. We view the Commission as a good idea, but those views were not included in the article.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
As Trump Administration Probes Long-Approved Medications, Could FDA Revoke Approvals?
Medscape March 6, 2025: MAHA Commission will study psychiatric, ADHD, and weight loss drugs’ impact on children. NCHR’s Diana Zuckerman agrees we need better evidence that the benefits of these drugs outweigh the risks.
Read More »The FDA’s misguided thinking on antibiotics
STAT, February 10, 2025: Why are so many people dying from infections? In this op-ed, Diana Zuckerman and John Powers discuss that the main problem isn’t antimicrobial resistance; the problem is the way antibiotics are studied and approved. Research shows we can save lives with better studies and FDA approval standards that focus on patients and not bugs.
Read More »Pfizer hires FDA drug regulator Cavazzoni, sparking revolving door debate
Politico, February 24, 2025: FDA Director of Drug Center (CDER), Cavazzoni, returns to Pfizer, where she worked before going to the FDA. NCHR and other experts say this revolving door undermines trust in the FDA and highlights concerns about the cozy relationship between the FDA and industry that can weaken standards of safety and effectiveness.
Read More »The Deadly Secrets Behind “Breakthrough” Alzheimer’s Drugs
The Lever, January 28, 2025: We are working with a consortium of experts to expose problems with FDA approvals. Our first article published in The Lever focuses on the clear risks and questionable benefits of drugs for early cognitive impairment caused by Alzheimer’s and how conflicts of interest resulted in approval.
Read More »